Roche said the late-stage study of its arthritis drug indicated that ocrelizumab could help ease symptoms of a type of rheumatoid arthritis.

Roche said its phase III trial found that ocrelizumab was responsive as a treatment for seropositive rheumatoid arthritis patients with a previous inadequate response to methotrexate (MTX).

When in combination with MTX, ocrelizumab alleviated symptoms of the disease at week 24 and 48 of the trial more than patients who were just being treated with MTX.